Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150702 | 0.81 | ABL1 (0.45) | MAPK1NPC1RAB9AMAPTMEN1 | |
| SCHEMBL4984623 | 0.81 | MAOA (0.42) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL28792255 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL119906 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL4295622 | 0.79 | MAOA (0.48) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL19783319 | 0.79 | CYP1A2 (0.41) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL15180071 | 0.77 | CA1 (0.47) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL15068207 | 0.76 | CA12 (0.41) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL2056246 | 0.75 | CYP1A2 (0.40) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 | |
| SCHEMBL4988758 | 0.75 | ERN1 (0.53) | CYP3A4CYP1A2CYP2A6CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175086-A1 | ARYL TRICYCLIC STING AGONIST AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-03 | — | — | US | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| EP-2797888-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2014-11-05 | — | — | EP | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | CYP3A4 1638/4885CYP1A2 593/4885CYP2A6 1679/4885 |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CYP3A4 2432/4885CYP1A2 3859/4885CYP2A6 3868/4885 |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CYP3A4 3051/4885CYP1A2 3983/4885CYP2A6 4037/4885 |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BRAF, RAF1, ARAF | CYP3A4 2432/4885CYP1A2 3859/4885CYP2A6 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.